drugset / Trial / NCT06786026
QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is to evaluate the efficacy and safety of QL1706 plus albumin-bound paclitaxel ± bevacizumab in 1L treatment of r/mTNBC
Timeline
- Start
- 2024-10-09
- Primary completion
- 2025-09-30
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | QL1706 | Monoclonal antibody | — | — |
| Background | Paclitaxel | Small molecule | — | — |